BNET Industries
Market Cap:$15.1B
Last Fiscal Year Sales:$15.6B
- Public
- NL
Dow Jones Description
Akzo Nobel's paint colors turn the competition green. Founded in 1911 and headquartered in Arnhem, Netherlands, Akzo Nobel N.V. (NASDAQ: AKZOY (ADR); AMS: AKZA) is the world's largest paint maker, among other businesses. The company operates in several segments. Coatings segment produces paints, stains, chemicals, auto finishes, and synthetic resins. Pharmaceuticals segment produces prescription and over-the-counter drugs. Chemicals segment produces specialty, functional, and commodity chemicals. The company has annual revenue of about ?13 billion and employs about 61,500 people. Akzo Nobel was listed on FTSE4Good Index in 2006. In 2005 it was selected as a member of the prestigious Dow Jones Sustainability Indexes, World and Stoxx.
Chairman & CEO
G.J. WijersNumber of Employees 42,600
Peer Companies
NAICS Code Medicinal and Botanical Manufacturing: 325411
Recent Events
-
2nd UPDATE: Akzo 3Q Net Profit Up, Fiscal Year Outlook Missing
-
UPDATE: AkzoNobel 3Q Net Profit Up 30%, No Full-Year Outlook Given
-
Kemira to buy Akzo Nobel's iron coagulant business in Nordic countries
-
BRIEF-RESEARCH ALERT-Goldman cuts Givaudan to sell; raises Syngenta, DSM to buy
-
Akzo profit a sign chemical makers have potential to surprise
-
2nd UPDATE: AkzoNobel 2Q Net 13% Down, No Fiscal Year Outlook Given
-
Akzo Nobel reports 13% decline in 2Q net income to Euro 155 million for 2009
News & Analysis
Filter by
akzo nobel n.v. and diosynth - All News and Analysis
As of 1st January 2005, Organon and Diosynth of Pharmaceutical Giant Akzo Nobel Were Integrated into One Business Unit
DUBLIN, Ireland -- Headquartered in the Netherlands, Akzo Nobel is active in three areas: pharmaceuticals, coatings and chemicals. The pharmaceuticals division consists of three businesses, Organon, Intervet and Diosynth, which manufacture products for both human and animal healthcare. As of 1st January 2005, Organon and Diosynth were integrated into one...
As of 1st January 2005, Organon and Diosynth of Pharmaceutical Giant Akzo Nobel were integrated into one business unit.
M2 PRESSWIRE-17 October 2005-Research and Markets: As of 1st January 2005, Organon and Diosynth of Pharmaceutical Giant Akzo Nobel were integrated into one business unitC1994-2005 M2 COMMUNICATIONS LTD RDATE:19102005 Headquartered in the Netherlands, Akzo Nobel is active in three areas: pharmaceuticals,...
Pharmaceuticals intermediates: Suppliers to the drug industry are trying to stay ahead of competitors, customers, and technologies. (Cover Story).(Brief Article)
Fine chemicals makers supplying the pharmaceuticals industry say they are scrambling for the best positions in an increasingly tricky game. Demand growth is returning to the $24-billion/year fine chemical merchant market that includes contract manufacturing drug intermediates and active pharmaceutical ingredients API, and most signs point...
AKZO NOBEL'S PHARMA ON COURSE FOR DOUBLE-DIGIT GROWTH.(financial outlook and management strategies for Pharma Group and other Akzo Nobel busines units)(Company Profile)(Statistical Data Included)
Akzo Nobel's recently restructured Pharma Group is primed to deliver double-digit growth this year on a business-like basis. The restructuring has strengthened the Group's strategic focus on prescription pharmaceuticals, animal healthcare and complex active pharmaceutical ingredients APIs, providing a solid basis for continuing...
Akzo Nobel's Pharma On Course for Double-Digit Growth
Business Editors & Health/Medical Writers ARNHEM, Netherlands--BUSINESS WIRE--Oct. 9, 2001 Akzo Nobel's recently restructured Pharma Group is primed to deliver double-digit growth this year on a like-business basis. The restructuring has strengthened the Group's strategic focus on prescription pharmaceuticals, animal healthcare and complex active pharmaceutical ingredients APIs, providing...
- 1
Decision Makers
| Name (plus bio) | Position |
|---|---|
| R.J. Frohn | CFO |
| Rob Frohn | CFO |
| Keith Nichols | Senior Vice President, Finance |
| O. Werner | Senior Vice President, HR |
| Jan H. Dopper | Technology Director |
| John McLaren | Director, Corp Communications |
| M. Rooseboom | Senior Group Director, Coatings |
| Barry Oonk | Manager, Advertising |
| Bill McPherson | General Manager, Marine & Protective Coatings |
| Rob Molenaar | General Manager, Powder Coatings Business |
| A. Jan Eijsbouts | General Counsel |
| A.T.M. Wilderbeek | Member, Management Bd, Pharma |
| Han Jalink | Secretary |
| Leif Darner | Head |
| Rudy M.J. van der Meer | Member, Management Bd, Coatings |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| G.J. Wijers | Chairman & CEO |
| Antony Burgmans | Supervisory Board |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Chairman & CEO | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | CFO | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | CFO | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Senior Vice President, Finance | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Senior Vice President, HR | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Technology Director | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Director, Corp Communications | Current |
| Akzo Nobel N.V. | Director, Corp Communications | Former |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Senior Group Director, Coatings | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Manager, Advertising | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | General Manager, Marine & Protective Coatings | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | General Manager, Powder Coatings Business | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | General Counsel | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Member, Management Bd, Pharma | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Secretary | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Head | Current |
| Organization | Position | Status |
|---|---|---|
| Akzo Nobel N.V. | Member, Management Bd, Coatings | Current |
| James Hardie Industries N.V. | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Amoco Ultimate | Board of Directors | Current |
| Bp Alternative Energy | Board of Directors | Current |
| Air Bp Limited | Board of Directors | Current |
| Bp Refining and Petrochemical | Board of Directors | Current |
| Progas Limited | Board of Directors | Current |
| The Bp Group | Board of Directors | Current |
| Bp Solar Neighbors Program | Board of Directors | Current |
| Akzo Nobel N.V. | Supervisory Board | Current |
| Bp Solar International, Inc. | Board of Directors | Current |
| Bp Marine | Board of Directors | Current |
| AEGON N.V. | Supervisory Board | Current |
| BP plc | Board of Directors | Current |
| Wristore | Board of Directors | Current |
| Unilever N.V. | Business Group Vice President | Former |
| Unilever | Marketing Assistant | Former |
| Unilever N.V. | Chairman, Unilever Indonesia | Former |
| Unilever N.V. | Chairman | Former |
| Unilever N.V. | Vice Chairman | Former |
| Unilever Plc | Vice Chairman | Former |
| Unilever | Board of Directors | Former |
| University of Lancaster | MA | Former |
| Nijenrode University | Former | |
| University of Stockholm | Former |
| Volume | 1,105 |
| Shares Outstanding | 231.6M |
| Market Cap | 15.1B |
| Year High | 70.00 |
| Year Low | 30.35 |
| Earnings Per Share | -6.7840 |
| P/E Ratio | N/A |
| Dividend | 1.94 |
| Yield | 2.9738 |
Industry Transcripts by Seeking Alpha
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes

